



*School of*  
**COMMUNITY  
MEDICINE**

University of Oklahoma – Tulsa  
Clinical Vignette Symposium 2025

**Call for Abstracts &  
Conference Information**

Sponsored by:  
Tulsa County Medical Society &  
Office for Research Development and Scholarly Activity



**Tulsa County Medical Society  
FOUNDATION**  
Physicians Caring for the Community

**ORDSA**

Dear Colleagues,

On behalf of the OU School of Community Medicine, I am pleased to offer this call for abstracts for the 14th annual Clinical Vignette Symposium (CVS), sponsored by the Tulsa County Medical Society. CVS is an opportunity to present your case reports in a conference setting. CVS is also an opportunity to tell your story of great cases you have seen.

Case studies are a crucial part of exploratory scholarly activity. They disseminate new knowledge and allow for collaborative learning. Case studies play an important role in inspiring new research. We encourage abstracts based on unusual or exciting clinical cases you have been involved with during your education here at the School of Community Medicine.

This year, CVS will take place in March and the abstracts that are accepted will be presented at two poster sessions on *Wednesday, March 26, 2025*, in the Learning Center's Founders Hall. Most will be in poster format, but we will choose two abstracts to be presented orally during the event. The authors will also upload their posters to the Open Science Framework (OSF). This platform allows other researchers around the world to view the posters and will be citable on your CV.

Please review the enclosed instructions. The deadline for all submissions is Friday, January 31, 2025.

We look forward to reviewing your abstract and seeing you at our symposium.

Sincerely,



Martina Jelley, MD, MSPH, FACP

Professor and Vice Chair for Research, Department of Internal Medicine

Julian Rothbaum Chair in Community Health Research

Assistant Dean for Clinical Research

University of Oklahoma School of Community Medicine

## Table of Contents

About the Conference .....	4
Important Dates and Deadlines.....	4
Abstract Submission Information.....	5
Guide for Authors.....	8
Poster & Day-Of Information .....	9
Sample Abstract.....	11
2024 Winners .....	12


## About the Conference

CVS will take place on Wednesday, March 26, 2025, from 4:00pm – 7:00pm. There will be two poster sessions. The first session will take place from 4:00 – 5:00pm and the second session will take place from 6:00 – 7:00pm.

All accepted posters will be displayed in the Learning Center’s Founders Hall during the conference. Two selected abstract authors will also give oral presentations during the event. Authors will also be able to upload their accepted posters into the Open Science Framework to disseminate their work to a wider audience.

## Important Dates and Deadlines

Abstract Submission Portal Opens	December 6, 2024
Abstract Submission Deadline	January 31, 2025
Abstract Review Deadline	February 16, 2025
Acceptance Notifications	February 18, 2025
Revise & Resubmit Deadline	February 23, 2025
Poster Printing & OSF Upload Deadline	March 21, 2025
Clinical Vignette Symposium	March 26, 2025



## Abstract Submission Information

### Accessing the Abstract Submission Site

You will submit your abstract at <https://cvs2025.exordo.com>.

The submission deadline of **Friday, January 31, 2025**, is final. Late or incomplete submissions ***will not be accepted***.

### Abstract Categories

- Emergency Medicine
- Family and Community Medicine
- Internal Medicine
- Obstetrics and Gynecology
- Pediatrics
- Psychiatry
- Surgery

### Abstract Format Requirements

Abstracts are limited to 400 words.

Titles must be in title case and limited to 12 words. An example of title case:  
**N**asal **P**olyps **L**eading to **N**ewly **D**iagnosed **C**ystic **F**ibrosis in an **A**dolescent

Abstracts must be provided in a structured format: Introduction, Case Description, Discussion. Any concluding remarks can be included in the Discussion section of the abstract.

All authors' names, affiliations, designations, credentials, and emails must be entered into the submission portal system. Please make sure you have this complete information ready prior to abstract submission.

All abstracts should be reviewed by a faculty mentor and departmental research facilitator before submitting. Check with your department chair or faculty advisor if you don't know who your departmental research facilitator is.

*The presenting author must agree to be present during the duration of the Clinical Vignette Symposium. **Please do not submit an abstract if you know you are not available on March 26, 2025, from 4:00-7:00pm.** If an abstract has been accepted and a presenting author is unable attend CVS, the submission will be withdrawn from consideration prior to the event.*

## Abstract Review

Peer reviewers in a related field will review submissions to determine if they meet best practices. You will be notified if the abstract has been accepted or rejected by **Tuesday, February 18, 2025**. This gives you time to prepare and print a poster, and to upload your presentation file to the Open Science Framework before the applicable deadlines. Review the “Important Dates and Deadlines” section (above) and if you think you might need more than the time allotted to prepare your poster, you can begin working on it as soon as you submit your abstract.

In addition to the two selected oral presenters, winners for first, second, and third place will be announced.

## Authorship

“*Presenting Author*” is defined as the author designated with presenting the abstract at the Clinical Vignette Symposium. This individual is also responsible for providing the required information for all authors included in the submission. Only one presenting author can be selected per submission. If selected as a winner of CVS, travel or publication fee support will be awarded to the presenting author.

“*Corresponding Author*” is defined as an author responsible for receiving and responding to messages from the CVS planning committee and the ORDSA team regarding the submission and event information. We strongly encourage the presenting author and the corresponding author to be the same person, as most information is pertinent to presenting authors. However, more than one corresponding author can be selected per submission.

**A presenting author may submit up to two abstracts.** However, they may be listed as co-author on an unlimited number of other abstracts. If a presenting author has two abstracts accepted, they will be required to submit two posters and present at both sessions of CVS.

**Preclinical medical students (MS1 and MS2) are permitted to present at CVS but must receive mentorship from both a faculty member and a research coordinator in the applicable SCM department on their presentation.** We strongly encourage the inclusion of a care-providing resident who participated in the case to provide their clinical expertise on the submitted abstract.

A faculty mentor ***must approve of the submission*** in addition to being listed as an author on the final submitted abstract. Please ensure that your mentoring faculty is listed as an author on your submission. **ORDSA may contact the faculty mentor of a submitted abstract to confirm approval if necessary.**

It is the responsibility of the presenting author to ensure that all co-authors are aware of the contents of the abstract and the submission is their own work in collaboration with the other authors listed. Incomplete author information may cause the abstract to be rejected. See the example below of how to list the affiliations of your co-authors.

#### Affiliation Examples

University of Oklahoma School of Community Medicine, Department of Family & Community Medicine

University of Oklahoma School of Community Medicine, Department of Pediatrics

## Guide for Authors

Reviewers will consider the following questions as they read through the abstract submissions:

- Introduction: Does the introduction provide subject, purpose, and value of case report?
- Does it present background information and include evidence of literature review?
- Case Description: Does the case description provide a description of the case and include only information applicable to the case?
- Does it include results of physical exam, lab or diagnostic data, final diagnosis, and treatment of patient post-diagnosis?
- Discussion/Conclusion: Does the discussion/conclusion review the treatment decisions, evaluate case for accuracy, validity, and rarity?
- Does it compare the case to the current literature, include recommendations, and present a clear teaching point or lesson learned from the case?
- Readability: How easy is it to understand the submission?

### Additional Resources

Information about Preparing a Clinical Vignette (Case Report) Abstract

<https://www.acponline.org/membership/residents/competitions-awards/acp-national-abstract-competitions/guide-to-preparing-for-the-abstract-competition/writing-a-clinical-vignette-case-report-abstract>

### Race in Clinical Case Presentations

Recent literature recommends not including race in case descriptions unless it is relevant to the case. For this reason, consider omitting race from your abstract. For more information, see [this article](#).



## Poster & Day-Of Information

Information about Preparing a Poster Presentation

<https://www.acponline.org/membership/residents/competitions-awards/acp-national-abstract-competitions/guide-to-preparing-for-the-abstract-competition/preparing-a-poster-presentation>

### Poster Printing

Once your abstract has been accepted, presenters will need to follow the below instructions.

Presenters are encouraged to use a standardized poster template. You can access the template [here](#). You may also use your department approved poster template.

Information on pricing for poster printing services provided by the OU-Tulsa Schusterman Library can be found [here](#). Some departments help with the cost of printing. Check with your mentor for details. If the department is unable to help with your printing costs, you can visit any office or off-campus printing stores for pricing. You may also contact [ORDSA@ouhsc.edu](mailto:ORDSA@ouhsc.edu) for possible support and additional resources.

If you select to use the OU-Tulsa Schusterman Library to print your poster, please note the abstract must be submitted for printing by **Friday, March 21, 2025, at 5:00pm**.

Posters wider than 48 inches WILL NOT be permitted due to the size limitation of our display boards.

### Poster Upload to Open Science Framework

In order to be considered for one of the three top prizes at the Clinical Vignette Symposium, presenters will need to upload the completed poster to the [OSF Meeting](#) site. To upload your poster, send an email to [CVS2025-poster@osf.io](mailto:CVS2025-poster@osf.io) from the email account you would like use for your OSF account. The format of the email should be as follows:

- Subject: Presentation title (Please use complete title on poster)
- Message body: Presentation abstract text
- Attachment: Your presentation file (e.g., PowerPoint, PDF)

OSF will follow up by sending a permanent identifier that others can use to cite your work on your CV. You will also be able to login to OSF and make changes to your submission if necessary. Learn more with this [Help Guide from OSF Meetings](#).

### Day-Of Details and Judging Information

Clinical Vignette Symposium will take place in two poster sessions on Wednesday, March 26, 2025, from 4:00pm – 7:00pm. **You may hang your poster in Founders Hall that morning, from 9:00am – 11:00am.** If you are not available during that time, you must find someone to hang your poster for you. Be prepared to provide the presenting author's name, the poster title, and/or the submission ID number when arriving to hang your poster. Velcro used to hang the posters will be provided.

Any accepted submission whose poster is not hung by 12:00pm on Wednesday, March 26, 2025, will be withdrawn from consideration.

You will be assigned to Poster Session 1, an oral presentation, or Poster Session 2. If you are presenting two posters, one poster will be assigned to Poster Session 1 and one poster will be assigned to Poster Session 2. The oral presentation component is by invitation only. Assigned reviewers will identify people for this portion of CVS.

The day will be structured as follows:

4:00 – 5:00pm	Poster Session 1
5:10 – 5:50pm	Oral Presentations
6:00 – 7:00pm	Poster Session 2

Notification of poster session will occur at least one week prior to the event.

The presenting author must be available for the entire duration of the poster session to which they are assigned. They should be prepared to make a short presentation to the judges (no more than three to five minutes). Judges may not be in your field of study so the presentation should be for a general audience.

### Withdrawals

If you are unable to attend CVS and/or need to withdraw your submission for any reason, please e-mail [ORDSA@ouhsc.edu](mailto:ORDSA@ouhsc.edu) with your name, poster title, and submission ID number.

## Sample Abstract

### Multi-drug Resistant Mycobacterium Abscessus Osteomyelitis Following an ATV Accident

Janitzio Guzman, Emily Bolender, Samie Sabet, Kimberly Martin

**INTRODUCTION:** Mycobacterium abscessus (MA) is a rapidly-growing nontuberculous mycobacterium (NTM) found in water and soil that causes pulmonary, skin/soft tissue, and bone infections. Treatment of MA infections is difficult as there is extensive antimicrobial resistance and no consensus among experts on one standard regimen. Agents such as amikacin, ceftazidime, clofazimine, and omadacycline have been used in the treatment of this infection.

**CASE DESCRIPTION:** A previously healthy 15-year-old female presented for evaluation of an open midshaft fracture with visible contamination of the tibia and fibula after an ATV accident. She underwent surgical debridement and open fracture repair. Over the following two months, she had multiple readmissions for repeat debridement, and was placed on IV antibiotics for treatment of osteomyelitis due to numerous organisms. While these organisms were not recovered on subsequent intraoperative cultures, she did not have tissue healing as expected for her injury, prompting empiric expansion of therapy until acidfast bacillus culture returned positive for *M. abscessus* sub. *bolletii*. Therapy was thus expanded to include clarithromycin and meropenem. Based on susceptibilities, the therapy was changed to amikacin, ceftazidime, and linezolid. Repeat debridements were undertaken, resulting in clearance of cultures five weeks after MA was isolated. All interim hardware was removed but an intermedullary rod was required given non-union of the tibia. Antibiotics were continued with excellent wound healing. Despite initial tolerance, after six months the patient experienced increasing serum creatinine and decreasing white blood cell count, concerning for potential amikacin and linezolid toxicities, respectively. In consultation with MA experts, the decision was made to transition to oral therapy with clofazimine, linezolid, and omadacycline. To date, laboratories are not suggestive of infection recurrence.

**DISCUSSION:** MA is a rapidly-growing NTM uncommonly encountered in healthy children; however, MA resistance to multiple agents is common. Current data does not support a single standard therapeutic regimen. Rather, the infection usually requires a prolonged courses of antimicrobials particularly in presence of hardware. This patient tolerated her initial regimen for the majority of her course, but she began to demonstrate evidence of possible nephrotoxicity and myelosuppression. Due to these abnormalities and the absence of data suggesting a clear total duration of therapy, transition to an oral regimen of clofazimine, omadacycline, and linezolid was planned. While the literature supporting clofazimine use for this indication is scant, for omadacycline it is limited to a NTM pulmonary case. This case highlights the need for study and identification of safe and efficacious NTM susceptible antibiotics.

## 2024 Winners

Thank you to everyone who participated in the 2024 Clinical Vignette Symposium. Congratulations to the following CVS winners and oral presenters:

### 1st Place

#### **Nasal Polyps Leading to Newly Diagnosed Cystic Fibrosis in an Adolescent**

Winning Author: Dr. Noelia Swymeler - OU-TU School of Community Medicine, Department of Pediatrics

Co-authors: Dr. Darby Sparks, Dr. Michelle Escala, Dr. Susan Studebaker, Dr. Michelle Condren, Dr. Joseph Walter

### 2nd Place

#### **Accidental Gunshot Wound in Pediatric Patient**

Winning Author: Rachel Bright - OU-TU School of Community Medicine

Co-authors: Dr. Amna Obaid, Dr. Laura Stuemky, Dr. Laura Campion

### 3rd Place (tie)

#### **Failure to Thrive Leading to Delayed Diagnosis of Severe Coarctation of the Aorta**

Winning Author: Hannah Williams - OU-TU School of Community Medicine

Co-authors: Dr. Kyle Bielefeld, Dr. Lauren Conway

#### **Atypical Presentation of DRESS Syndrome in an African American Male**

Winning Author: Dr. Jazeb Ifikhar - OU-TU School of Community Medicine, Department of Pediatrics

Co-authors: Dr. Laura Campion, Dr. Weyman Lam

### Oral Presenters

#### **Nasal Polyps Leading to Newly Diagnosed Cystic Fibrosis in an Adolescent**

Winning Author: Dr. Noelia Swymeler - OU-TU School of Community Medicine, Department of Pediatrics

Co-authors: Dr. Darby Sparks, Dr. Michelle Escala, Dr. Susan Studebaker, Dr. Michelle Condren, Dr. Joseph Walter

#### **Hyperthermia: A Unique Presentation of Sympathomimetic Toxicity**

Winning Author: Dr. Joshua Miller - OU-TU School of Community Medicine, Department of Emergency Medicine

Co-author: Dr. Lori Whelan